Cancer Therapy Based On Anatomical Lo...

Cancer Therapy Based On Anatomical Location May Soon Be Obsolete

There are 1 comment on the Pharma-lexicon.com story from Apr 23, 2006, titled Cancer Therapy Based On Anatomical Location May Soon Be Obsolete. In it, Pharma-lexicon.com reports that:

The results of a new study at Washington University School of Medicine in St. Louis could eventually have oncologists removing their specialties from their shingles by making therapy based on a tumor's ...

Join the discussion below, or Read more at Pharma-lexicon.com.

gdpawel

Philadelphia, PA

#1 Apr 23, 2006
What a cancer patient would like ideally, is to know whether they would benefit from adjuvant chemotherapy (Molecular profiling). If so, which active drugs have the highest probability of working (Cellular profiling) and are relatively non-toxic in a given patient (Pharmacologic profiliig).

By utilizing Molecular profiling oncologists can identify those patients unlikely to benefit from adjuvant chemotherapy from those that would. If the patient needs adjuvant chemotherapy, utilizing Cellular and Pharmacologic profiling, the oncologist can select drugs that have a higher probability of being effective for an individual patient rather than selecting drugs based on the average responses of many patients in large clinical trials.

It's not one versus the other. The best thing is to combine these different tests in ways which make the most sense. One month's worth of herceptin + avastin costs approximately $8000. That's without any docetaxel and blood cell growth factors and anti-emetics. If nothing else, we can't afford too much trial and error treatment.

There are patients who have progressive disease after first-line therapy, only to enjoy a dramatic benefit from second or even third line therapy, and these patients would have been much better served by receiving the most probable active treatment "the first time around."

There should be an expansion of reimbursement to promote even greater utilization and development of these laboratory-based mechanisms for improving the match between tumors and an ever-increasing number of partially effective and very expensive drug therapies.

These laboratory tests are a tool for the oncologist. The oncologist should take advantage of all the tools available to him/her to treat a patient. And since studies show that only 25-30% of patients do respond to chemotherapy that is available to them, there should be due consideration to looking at the advantage of these tests to the resistance that has been found to chemotherapy drugs.

We can't afford anymore 'trial-and-error' treatment.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Pharmacology Discussions

Title Updated Last By Comments
5ht2b antagonist Jan '17 aransheehan 1
Pharmacology Review Quiz is now from paid to free? Nov '16 CollinHarrams 1
News Where to buy dichloroacetate... (Jul '07) Oct '16 JIM 49
FDA: Adverse Reactions Website (May '08) Aug '16 jrdrmotwani 2
On binding plasma proteins... (Apr '15) Aug '16 jrdrmotwani 2
Dose-dependent or not (Mar '16) Mar '16 sam 1
News Could Music Be the Next Great Cure? (Apr '09) Aug '15 Tijesuni 8
More from around the web